Welcome to our dedicated page for Smith & Nephew Plc SEC filings (Ticker: SNNUF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Smith & Nephew Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Smith & Nephew Plc's regulatory disclosures and financial reporting.
Smith & Nephew plc reported that several senior leaders purchased its American Depositary Shares on the New York Stock Exchange as part of the Company’s Employee Stock Purchase Plan. The financial instrument is described as Smith & Nephew plc SPON ADR American Depositary Shares (ADS) with ISIN US83175M2052.
On 2026-01-16, these purchases were made at a price of $25.9 per ADS. Reported participants included Craig Gaffin (President, Global Orthopaedics) with a volume of 206.79536, Deepak Nath (Chief Executive Officer) with a volume of 410,10498, Paul Connolly (President, Global Operations) with a volume of 410.10498, and Scott Schaffner (President, Sports Medicine) with a volume of 242.58803, each noted as a single transaction.
Smith+Nephew has completed its acquisition of US-based Integrity Orthopaedics, the early-stage commercial developer of the Tendon Seam™ rotator cuff repair system. Tendon Seam™ is designed to significantly reduce re-tear rates and improve outcomes for patients undergoing rotator cuff repair.
The company paid an initial cash consideration of US$225 million, with additional performance-based payments of up to US$225 million over the next five years. Smith+Nephew states that this acquisition supports its RISE strategy to accelerate growth through strategic investment and portfolio leadership and is intended to be an important step toward becoming the global leader in Sports Medicine. Smith+Nephew generated $5.8 billion of sales in 2024 across more than 100 countries.
Smith+Nephew is acquiring US-based Integrity Orthopaedics, developer of the Tendon Seam™ rotator cuff repair system, to strengthen its Sports Medicine and shoulder repair portfolio. Rotator cuff repair is described as a substantial US market with around 500,000 procedures annually and an estimated value of $875 million. Tendon Seam™ uses patented micro-anchors and a continuous suture design, with early experience indicating lower re-tear rates, shorter sling times, and reduced procedure times versus standard methods, and has 510(k) clearance for soft tissue-to-bone reattachment.
Smith+Nephew will pay an initial US$225 million in cash plus up to US$225 million in performance-based payments over five years, funded from existing cash facilities, and states that leverage remains below its 2x EBITDA target. The transaction is expected to be accretive to Group trading profit margin by 2028 and to close before the end of January 2026. Management positions Tendon Seam™ alongside products such as the REGENETEN◊ Bioinductive Implant, Q-FIX◊ All-Suture Anchor and AETOS◊ Shoulder System, aiming to build one of the broadest shoulder repair and replacement offerings.
Smith & Nephew plc reports its latest share capital and voting rights position as at 31 December 2025. The company’s total issued share capital comprises 877,724,845 ordinary shares of US20¢ each, including 27,963,140 ordinary shares held in treasury. Because treasury shares do not carry voting rights, shareholders currently have 849,761,705 voting shares in issue, with one vote per share. Investors are advised that this voting share figure should be used as the denominator when assessing whether their holdings trigger notification obligations under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Smith+Nephew has launched its new RISE strategy and set ambitious 2028 financial targets, aiming for a 6–7% underlying revenue CAGR, 9–10% trading profit CAGR, more than $1 billion in free cash flow, and 12–13% post-tax ROIC, which is stated as being well above its WACC. For 2025, the company reiterates underlying revenue growth of around 5% and now expects a trading profit margin of at least 19.5% versus 18.1% in 2024, while upgrading expected free cash flow to around $800 million from an original target of more than $600 million; post-tax ROIC is expected to exceed 9% versus 7.4% in 2024. As part of portfolio rationalisation, Smith+Nephew plans to reduce gross inventory by around $500 million, supported by an estimated non-cash inventory provision of about $200 million in 2025. Provisional 2026 guidance calls for about 6% underlying revenue growth, free cash flow of around $800 million, and post-tax ROIC of more than 10%.
Smith & Nephew plc reports its current share capital and voting rights position. As at 30 November 2025, the company’s total issued share capital comprises 877,724,845 ordinary shares of US20¢ each, including 28,000,826 ordinary shares held in treasury. Because treasury shares do not carry voting rights, the number of shares with voting rights is 849,724,019 ordinary shares, each carrying one vote. Shareholders are advised to use this voting share figure as the denominator when assessing whether they must notify the UK regulator of any holdings or changes in their interest under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc filed a report showing that BlackRock, Inc. now holds a total of 7.17% of its voting rights, combining shares and financial instruments. On the date the threshold was crossed, BlackRock held 5.01% of voting rights attached to shares and 2.16% through financial instruments, representing 61,034,371 voting rights in total. Previously, BlackRock’s position was 4.95% via shares and 2.22% via financial instruments, with the overall percentage unchanged at 7.17%. The holding includes ordinary shares, American Depository Receipts and securities lending positions.
Smith & Nephew plc reported the vesting of a restricted share award for its Chief Executive Officer, Deepak Nath, granted on 29 April 2022. On 11 November 2025, 3,016 restricted shares vested, with a portion sold to meet tax obligations.
Of the vested shares, 1,240 shares were sold to cover taxes and 1,776 shares were retained. The transaction was recorded at a price of £12.573092 per share on the London Stock Exchange (XLON). The disclosure was made under the UK Market Abuse Regulation.
Smith & Nephew plc furnished a Form 6‑K containing a UK TR‑1 notice of major holdings. The notification shows BlackRock, Inc. with a total voting interest of 7.170000%, comprised of 4.950000% voting rights attached to shares and 2.220000% through financial instruments.
Total number of voting rights held in the issuer was 60,996,414. The prior notified position was 7.180000%. The financial instruments include American Depositary Receipts (869,113 voting rights; 0.100000%), securities lending (17,105,206; 2.010000%), and CFDs (936,898; 0.110000%).
Smith & Nephew plc reported routine share acquisitions by its CEO and senior executives under the Company’s Dividend Re‑Investment Plan. The purchases followed the 2025 interim dividend and were executed on 7 November 2025 on the London Stock Exchange (XLON) at £12.4048 per share.
Participants included Chief Executive Officer Deepak Nath (2,624.43651 shares), President, Sports Medicine Scott Schaffner (746.79305), President, Advanced Wound Management and Global Commercial Operations Rohit Kashyap (427.09066), President, Orthopaedics Craig Gaffin (197.25944), Chief Quality & Regulatory Affairs Officer Mizanu Kebede (4.1729), and President, Global Operations Paul Connolly (394.41542).
The transactions relate to ordinary shares of USD 0.20 each (ISIN: GB0009223206) and were disclosed under UK Market Abuse Regulation.